Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Colorcon
Boehringer Ingelheim
McKinsey
Medtronic

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,094,781

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,094,781 protect, and when does it expire?

Patent 7,094,781 protects OPSUMIT and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 7,094,781
Title:Sulfamides and their use as endothelin receptor antagonists
Abstract: The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
Inventor(s): Bolli; Martin (Allschwil, CH), Boss; Christoph (Allschwil, CH), Fischli; Walter (Allschwil, CH), Clozel; Martine (Saint-Louis, FR), Weller; Thomas (Binningen, CH)
Assignee: Actelion Pharmaceuticals Ltd. (CH)
Application Number:10/433,041
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,094,781
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,094,781

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Actelion Pharms Ltd OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,094,781

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/EP00/12890Dec 18, 2000
PCT Information
PCT FiledDecember 04, 2001PCT Application Number:PCT/EP01/14182
PCT Publication Date:July 11, 2002PCT Publication Number: WO02/053557

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKinsey
Dow
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.